ClinConnect ClinConnect Logo
Search / Trial NCT05645913

Association of Obesity and Cardiovascular Outcomes in Atrial Fibrillation

Launched by AJOU UNIVERSITY SCHOOL OF MEDICINE · Dec 2, 2022

Trial Information

Current as of July 12, 2025

Unknown status

Keywords

ClinConnect Summary

This clinical trial is looking at how obesity, measured by body mass index (BMI) and waist circumference, affects health outcomes in patients with atrial fibrillation (AF) who are taking blood-thinning medications called oral anticoagulants (OAC). The study focuses on patients across Asia who were diagnosed with AF between January 2015 and December 2020. Researchers want to understand if being overweight or obese influences the effectiveness of the treatment and overall health for these patients.

To be eligible for this trial, participants must be new users of OAC and diagnosed with AF within the specified timeframe. However, individuals under 20 years old, those with valvular AF, or those who may need OAC for other reasons, like recent surgery or cancer, cannot take part. If you or a loved one meet these criteria, you may be able to contribute to important findings that could help improve care for patients with AF in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Oral anticoagulant (OAC) new users diagnosed with atrial fibrillation (AF) between January 2015 and December 2020
  • Exclusion Criteria:
  • Patients aged \<20 years
  • Valvular AF patients
  • Possible alternative indications for OAC (pulmonary embolism, deep vein thrombosis, or recent joint replacement surgery)
  • Cancer patients

About Ajou University School Of Medicine

Ajou University School of Medicine is a leading academic institution dedicated to advancing medical research and education. Located in South Korea, the School of Medicine is renowned for its commitment to innovative clinical trials that aim to improve patient outcomes and enhance healthcare practices. With a focus on multidisciplinary collaboration, Ajou University fosters a research environment that integrates cutting-edge technologies and scientific inquiry. The institution is dedicated to ethical standards and regulatory compliance, ensuring the safety and welfare of participants in all clinical studies. Through its robust training programs and partnerships, Ajou University School of Medicine aims to contribute significantly to the global medical community.

Locations

Suwon, Gyeong Gido, Korea, Republic Of

Patients applied

0 patients applied

Trial Officials

Kwang-No LEE

Principal Investigator

Ajou University School of Medicine

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials